Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysergide SCHEMBL30949883 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL29349465 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL27221708 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL23741954 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL467940 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL24449764 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL113755 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL12401704 | 1.00 | HTR2A (1.00) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL22774200 | 0.99 | HTR2A (0.98) | HTR2ADRD3HTR2CADRB1HTR1A | |
| Lysergide SCHEMBL28855252 | 0.99 | HTR2A (0.98) | HTR2ADRD3HTR2CADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4584243-B1 | CROSSLINKERS | HEMOTEQ AG (DE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642780-A2 | PROCESS FOR SYNTHESIZING 2-BROMOLYSERGIC ACID DIETHYLAMIDE VIA CONTROLLED HYDROLYSIS OF BROMOCRIPTINE | Ceruvia Lifesciences LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4584244-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584243-A1 | CROSSLINKERS | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584245-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025056815-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056814-A1 | CROSSLINKERS | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056813-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| EP-4524128-A1 | BENZOPHENONE CROSSLINKERS | Hemoteq AG (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2024145604-A2 | PROCESS FOR SYNTHESIZING 2-BROMOLYSERGIC ACID DIETHYLAMIDE VIA CONTROLLED HYDROLYSIS OF BROMOCRIPTINE | CERUVIA LIFESCIENCES LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145546-A1 | PROCESS FOR SYNTHESIZING 2-BROMOLYSERGIC ACID DIETHYLAMIDE VIA CONTROLLED BROMINATION OF LYSERGIC ACID | CERUVIA LIFESCIENCES LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230286975-A1 | IMPROVED METHOD FOR THE PRODUCTION OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND NOVEL DERIVATIVES THEREOF | MIHKAL GMBH (CH) | 2023-09-14 | — | — | US | disclosed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4178956-A2 | IMPROVED METHOD FOR THE PRODUCTION OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND NOVEL DERIVATIVES THEREOF | COMPASS Pathfinder Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | HTR2A 8/4885DRD3 72/4885HTR2C 5/4885 |
| US-20230286975-A1 | IMPROVED METHOD FOR THE PRODUCTION OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND NOVEL DERIVATIVES THEREOF | HTR2A, HTR5A, HTR2C | HTR2A 1/4885DRD3 409/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.